Asset Management One Co. Ltd. Sells 409 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Asset Management One Co. Ltd. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 83,139 shares of the medical equipment provider’s stock after selling 409 shares during the period. Asset Management One Co. Ltd.’s holdings in Zimmer Biomet were worth $7,583,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Truist Financial Corp lifted its stake in Zimmer Biomet by 34.4% during the second quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock worth $2,446,000 after purchasing an additional 6,867 shares during the period. OneDigital Investment Advisors LLC bought a new position in Zimmer Biomet during the first quarter worth about $269,000. State of Alaska Department of Revenue lifted its stake in Zimmer Biomet by 89.8% during the second quarter. State of Alaska Department of Revenue now owns 44,261 shares of the medical equipment provider’s stock worth $4,036,000 after purchasing an additional 20,945 shares during the period. Thomasville National Bank lifted its stake in Zimmer Biomet by 3.0% during the second quarter. Thomasville National Bank now owns 105,805 shares of the medical equipment provider’s stock worth $9,650,000 after purchasing an additional 3,053 shares during the period. Finally, Bridge Creek Capital Management LLC lifted its stake in Zimmer Biomet by 12.3% during the second quarter. Bridge Creek Capital Management LLC now owns 30,133 shares of the medical equipment provider’s stock worth $2,748,000 after purchasing an additional 3,297 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $103.21 on Tuesday. The firm has a 50 day simple moving average of $101.87 and a 200 day simple moving average of $97.64. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72. The firm has a market cap of $20.45 billion, a P/E ratio of 25.11, a P/E/G ratio of 2.37 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the previous year, the business earned $2.01 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is currently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.39% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a research note on Thursday, September 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Raymond James Financial lifted their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Rothschild & Co Redburn started coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $111.94.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.